scholarly journals Effect of Communication Style on Perceptions of Medication Side Effect Risk among Pharmacy Students

2016 ◽  
Vol 80 (8) ◽  
pp. 131
Author(s):  
Ruta V. Sawant ◽  
Collin R. Beatty ◽  
Sujit S. Sansgiry
Keyword(s):  
Side Effect ◽  
Pharmacy Students ◽  
Communication Style ◽  
Medication Side Effect ◽  
Medication Side

scholarly journals Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

2017 ◽  
Vol 06 (04) ◽  
pp. 101-112
Author(s):  
Daniella C. Sisniega ◽  
Divya Madhusudhan ◽  
Elham Rahmani ◽  
Robert McInnis ◽  
Janice Weinberg ◽  
...  
Keyword(s):  
Side Effect ◽  
Safety Net ◽  
Medication Side Effect ◽  
Safety Net Hospital ◽  
Medication Side

The False Drug Side-Effect: Which Patients Complain

1968 ◽  
Vol 114 (507) ◽  
pp. 197-201 ◽  
Author(s):  
William S. Appleton
Keyword(s):  
Mental Health ◽  
Side Effects ◽  
Health Center ◽  
Side Effect ◽  
Mental Health Center ◽  
Young Female ◽  
Need For Care ◽  
Drug Induced ◽  
Medication Side Effect ◽  
Medication Side

At the Massachusetts Mental Health Center (M.M.H.C.), a well-staffed university psychiatric hospital, an outbreak of alleged chlorpromazine-induced skin rashes recently occurred involving five dramatic young female patients. Investigation of the complaints led us to doubt whether medication was the cause. Why then did these women blame chlorpromazine? Thus, the central concern of this investigation: which patients are likely to complain of drug-induced side-effects and under what conditions? A second issue arising from our study and described in the literature is the need for care when differentiating the true from the alleged medication side-effect.

Tolerance of aromatase inhibitors in post-menopausal patients with early-stage hormone receptor positive (HR+) breast cancer: A real-world retrospective analysis in a large oncotype database.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12532-e12532
Author(s):  
Shana Berwick ◽  
Brittney Shulman Zimmerman ◽  
Sara Malin Hovstadius ◽  
Julia Blanter ◽  
Erin Moshier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Endocrine Therapy ◽  
Aromatase Inhibitors ◽  
Median Duration ◽  
Side Effect ◽  
Early Stage ◽  
Medication Side Effect ◽  
Medication Side ◽  
Post Menopausal

e12532 Background: Aromatase inhibitors (AIs) compose the backbone of adjuvant endocrine therapy for early-stage HR+ breast cancer. Prior studies have demonstrated equivalence in efficacy between aromatase inhibitors in current clinical use. Thus choice of aromatase inhibitors is initially influenced by provider patterns and tailored based on adverse side effects. This study retrospectively evaluates the prevalence of intolerance to AIs warranting a change in therapy. Methods: We identified 181 post-menopausal patients with early-stage, HR+ breast cancer within a database of women who underwent oncotype testing at a large, urban medical center, with 167 (92%) receiving an AI. Patients were excluded if they had received chemotherapy. The Kaplan-Meier method was used to estimate median duration of endocrine therapy (ET). The Fisher’s exact test was used to compare proportions of patients requiring a switch in adjuvant AI and the Wilcoxon rank-sum test was used to compare age distributions. Results: Of the patients identified, 153 (90%) had stage IA disease with a median oncotype RS of 19. 167 (92%) patients received an AI as adjuvant therapy. Median duration of endocrine therapy (ET) was 83.5 months, with over 90% of patients on ET more than 5 years. Among the 152 patients with available data on ET interruptions, 52 (34%) patients had a change or interruption in their ET of these 40 (77%) were attributed to a medication side effect. The AI prescribed most frequently as initial therapy was anastrozole 138/165 (84%). 33 (24%) of patients who received anastrozole required a drug switch within the class, (no sig difference based on initial adjuvant therapy; p=0.4281). 12 (7%) patients required a switch from an AI to tamoxifen at some point during therapy. Changes in AI adjuvant therapy were most commonly attributed to joint pains 24 (46%), followed by hot flashes 2 (4%) and weight gain, 2 (4%). There was no statistically significant difference in median age between patients who interrupted ET due to medication side effect or other reason; p=0.2906. Conclusions: This study enforces previous findings that a significant proportion of women require a change in their adjuvant ET, most commonly due to adverse medication effects such as joint pain. The majority of the women in this database were initiated on anastrozole as initial adjuvant ET of whom 24% required a drug switch.[Table: see text]

Antipsychotic medications, glutamate, and cell death: A hidden, but common medication side effect?

2013 ◽  
Vol 80 (3) ◽  
pp. 252-258 ◽  
Author(s):  
Amanda M. Isom ◽  
Gary A. Gudelsky ◽  
Stephen C. Benoit ◽  
Neil M. Richtand
Keyword(s):  
Cell Death ◽  
Side Effect ◽  
Antipsychotic Medications ◽  
Medication Side Effect ◽  
Medication Side

A review of self-report medication side effect questionnaires for mental health patients

2014 ◽  
Vol 219 (3) ◽  
pp. 664-673 ◽  
Author(s):  
Deena Ashoorian ◽  
Rowan Davidson ◽  
Daniel Rock ◽  
Sajni Gudka ◽  
Rhonda Clifford
Keyword(s):  
Mental Health ◽  
Side Effect ◽  
Self Report ◽  
Medication Side Effect ◽  
Mental Health Patients ◽  
Medication Side
Sign in / Sign up

Export Citation Format

Share Document